Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER+/HER2- breast cancer.

Date publication

juillet 2025

Journal

Annals of oncology : official journal of the European Society for Medical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr LADOIRE Sylvain

Tous les auteurs :
Mamann A, Pradat Y, Bidard FC, Delaloge S, Cabel L, Faull I, Marques S, Bachelot T, Dalenc F, DE LA Motte Rouge T, Pistilli B, Samaniego J, Frenel JS, Levy C, Ferrero JM, Sabatier R, Ladoire S, Chakiba C, Hardy AC, Lemonnier J, Mahi Y, Andre F, Cournede PH, Michiels S, Bernard E

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40623476

Résumé

Patients with advanced estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer commonly develop resistance to treatment with hormone therapy and cyclin-dependent kinases 4/6 (CDK4/6) inhibitors. Responders cannot be distinguished from non-responders after the first cycle of treatment under current practice. We assessed circulating tumor DNA (ctDNA) measures at early time-points as prognostic markers.

Mots clés

ER+/HER2- advanced breast cancer, circulating tumor DNA, on-treatment dynamics, prognostic model, risk score, survival analysis

Référence

Ann Oncol. 2025 07 5;: